Efficacy and safety of golimumab in Crohn's disease: A French national retrospective study
Alimentary Pharmacology and Therapeutics Oct 18, 2017
Martineau C, et al. - The efficacy and safety of golimumab in Crohn's disease (CD) were described. Golimumab was safe and seemed beneficial in 50% of the patients after the failure of infliximab or adalimumab for Crohn's disease.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
